WAM
TEVA icon

Wolverine Asset Management’s Teva Pharmaceuticals TEVA Stock Holding History

Wolverine Asset Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.01K Sell
100
-260,100
-100% -$8.37M ﹤0.01% 1526
2025
Q4 		$8.12M Hold
260,200
– – 0.06% 274
2025
Q3 		$5.26M Hold
260,200
– – 0.04% 342
2025
Q2 		$4.36M Buy
260,200
+100
+0% +$1.61K 0.04% 362
2025
Q1 		$4M Buy
260,100
+10,100
+4% +$180K 0.05% 342
2024
Q4 		$5.51M Hold
250,000
– – 0.06% 298
2024
Q3 		$4.5M Hold
250,000
– – 0.05% 316
2024
Q2 		$4.06M Hold
250,000
– – 0.05% 327
2024
Q1 		$3.53M Buy
250,000
+249,100
+27,678% +$3.14M 0.04% 359
2023
Q4 		$9.4K Hold
900
– – ﹤0.01% 1392
2023
Q3 		$9.18K Hold
900
– – ﹤0.01% 1485
2023
Q2 		$6.78K Hold
900
– – ﹤0.01% 1440
2023
Q1 		$7.96K Sell
900
-202,900
-100% -$2.01M ﹤0.01% 1476
2022
Q4 		$1.86M Hold
203,800
– – 0.02% 589
2022
Q3 		$1.64M Sell
203,800
-130,000
-39% -$1.15M 0.02% 628
2022
Q2 		$2.51M Hold
333,800
– – 0.03% 492
2022
Q1 		$3.13M Sell
333,800
-407,400
-55% -$3.4M 0.03% 406
2021
Q4 		$5.94M Hold
741,200
– – 0.06% 278
2021
Q3 		$7.22M Buy
741,200
+200,000
+37% +$1.87M 0.06% 240
2021
Q2 		$5.36M Hold
541,200
– – 0.04% 261
2021
Q1 		$6.25M Sell
541,200
-215,700
-28% -$2.47M 0.05% 214
2020
Q4 		$7.3M Buy
756,900
+54,400
+8% +$521K 0.05% 209
2020
Q3 		$6.33M Buy
702,500
+309,400
+79% +$3.27M 0.06% 194
2020
Q2 		$4.85M Sell
393,100
-256,000
-39% -$2.9M 0.05% 221
2020
Q1 		$5.83M Buy
649,100
+98,600
+18% +$1.01M 0.08% 184
2019
Q4 		$5.39M Buy
550,500
+464,100
+537% +$4.14M 0.06% 238
2019
Q3 		$594K Hold
86,400
– – 0.01% 737
2019
Q2 		$797K Buy
+86,400
New +$1.04M 0.01% 725
2019
Q1 		– Sell
-455,200
Closed -$7.02M – 1690
2018
Q4 		$7.02M Buy
455,200
+174,000
+62% +$3.57M 0.08% 222
2018
Q3 		$6.06M Hold
281,200
– – 0.07% 273
2018
Q2 		$6.84M Sell
281,200
-74,200
-21% -$1.51M 0.09% 219
2018
Q1 		$6.07M Sell
355,400
-206,600
-37% -$4.03M 0.08% 238
2017
Q4 		$10.6M Buy
562,000
+266,300
+90% +$4.01M 0.11% 163
2017
Q3 		$5.2M Buy
295,700
+76,100
+35% +$1.71M 0.06% 252
2017
Q2 		$7.29M Buy
219,600
+58,800
+37% +$1.82M 0.09% 184
2017
Q1 		$5.16M Buy
160,800
+68,500
+74% +$2.34M 0.08% 221
2016
Q4 		$3.35M Buy
92,300
+14,600
+19% +$583K 0.04% 306
2016
Q3 		$3.57M Sell
77,700
-60,300
-44% -$3.15M 0.05% 307
2016
Q2 		$6.93M Buy
138,000
+136,761
+11,038% +$7.28M 0.11% 203
2016
Q1 		$807K Buy
1,239
+758
+158% +$44.5K 0.02% 429
2015
Q4 		$92K Buy
+481
New +$29.7K ﹤0.01% 1020
2014
Q3 		– Sell
-123
Closed -$2K – 2662
2014
Q2 		$2K Hold
123
– – ﹤0.01% 2186
2014
Q1 		$5K Sell
123
-257
-68% -$11.9K ﹤0.01% 1985
2013
Q4 		$265K Hold
380
– – 0.01% 1039
2013
Q3 		$334K Sell
380
-41
-10% -$1.6K 0.01% 929
2013
Q2 		$311K Buy
+421
New +$16.4K 0.01% 930

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wolverine Asset Management's TEVA Position: Q1 2026 in Review

Wolverine Asset Management opened a new position in Teva Pharmaceuticals (TEVA) in Q1 2026: 1 share worth $30. The stake represents ﹤0.01% of the portfolio and ranks #1665 among its holdings. This is a return to the name: Wolverine Asset Management previously reported a position in TEVA as recently as Q1 2023.

Wolverine Asset Management first reported a position in TEVA in Q2 2013 and has held it in 35 quarters since. The position peaked at $13.6M in Q2 2018. 650 funds tracked by Wall St. Rank hold TEVA as of Q1 2026.

  • Wolverine Asset Management held 1 share of Teva Pharmaceuticals worth $30 as of Q1 2026.
  • Teva Pharmaceuticals was a new Wolverine Asset Management position in Q1 2026.
  • Teva Pharmaceuticals made up ﹤0.01% of Wolverine Asset Management's portfolio in Q1 2026, its #1665 holding.
  • Wolverine Asset Management first reported a position in Teva Pharmaceuticals in Q2 2013 and has held it in 35 quarters since.
  • Wolverine Asset Management's Teva Pharmaceuticals position peaked at $13.6M in Q2 2018.
  • 650 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2026.

Based on Wolverine Asset Management's 13F filing for Q1 2026, filed 4 May 2026.